Free Trial
→ Rent out your stocks? (From Profits Run) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q2 2026 Earnings Results & Report

BioVie logo
$1.22 +0.02 (+1.75%)
As of 09:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioVie beat analyst earnings expectations in its Q2 2026 results, released February 6, 2026. The company reported EPS of -$0.77 versus the -$0.81 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

BioVie EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.81
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

BioVie's Q1 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q2 2026 Quarterly reportQuarterly report
(10-Q)

BioVie Q2 2026 Earnings FAQ

BioVie (NASDAQ:BIVI) reported earnings of -$0.77 per share for Q2 2026, beating the consensus estimate of -$0.81. The report was announced on Friday, February 6, 2026.

BioVie's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for BioVie on the company's earnings history page.

BioVie Earnings Headlines

BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380674/0/en/biovie-to-present-new-bezisterim-findings-in-parkinson-s-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting.html
BioVie (NASDAQ:BIVI) Raised to "Hold" at Wall Street Zen
October 11 at 1:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106660
AI Microcap Teams With Gentex on Next-Gen Military Helmets
Morgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion robots operating worldwide. But even the most advanced machines still lack one human sense: smell. One microcap is developing an AI-powered sensor, smaller than a deck of cards, now in hands-on integration with Gentex, whose helmet systems serve U.S. forces and more than 20 NATO nations.tc pixel
October 14 at 1:00 AM  |  Capital Trends (Ad)
BioVie (NASDAQ:BIVI) Downgraded by Wall Street Zen to Sell
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081392
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
September 26, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/44764/new-to-the-street-show-773-premieres-tonight-on-bloomberg-television-featuring-glint-sagtec-global-biovie-and-safespace-global/
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
September 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949122-biovie-inc-bivi-discussion-of-phase-2-data-on-bezisterim-in-long-covid-and-parkinsons-with
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for complex diseases with significant unmet medical needs. Its research programs have centered on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, as well as liver diseases associated with cirrhosis.

The company’s development portfolio has included NE3107, an investigational oral therapy being studied for potential anti-inflammatory and insulin-sensitizing effects in neurodegenerative conditions. BioVie has also developed BIV201, a continuous-infusion formulation of terlipressin intended for the treatment of ascites associated with liver cirrhosis. These products remain investigational and are not approved for commercial use in the United States.

BioVie conducts its drug-development activities primarily through clinical research and regulatory programs in the United States, working with research institutions, clinical investigators and other development partners. The company is headquartered in Nevada and has historically focused its resources on advancing its candidate therapies through clinical testing and potential regulatory approval.

BioVie’s leadership has included Chief Executive Officer Cuong Do, who has experience in the biopharmaceutical and healthcare industries. As a development-stage biotechnology company, BioVie does not currently operate a broad commercial product business and remains dependent on the progress of its clinical programs.

View BioVie Profile
Earnings Tools